Systematic review and meta-analysis estimate low prevalence of neurological adverse events in cancer patients treated with immune checkpoint inhibitors.
Key Points
To estimate the prevalence of neurological adverse events associated with immune checkpoint inhibitors in cancer treatment.
Conducted a systematic review and meta-analysis of 31 clinical trials.
Included data from 8,826 patients with cancer treated with immune checkpoint inhibitors.
Analyzed prevalence of neurological adverse events and performed subgroup analyses by cancer type.
Pooled prevalence of neurological adverse events was 1.78 ×10 -3 % (95%CI: 1.06×10 -3 %-2.78 ×10 -3 %).
No significant difference in prevalence between trials using one ICI (1.83×10 -3 %) and two ICIs (0.90×10 -3 %).
Most common adverse events were peripheral neuropathy (1.34×10 -3 %), myositis (0.78 ×10 -3 %), and aseptic meningitis (0.71×10 -3 %).